--- a
+++ b/clusters/9knumclustersv2/clust_1144.txt
@@ -0,0 +1,28 @@
+Have core biopsy or other minor surgical procedures within  days prior to the first dose of bevacizumab
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
+Minor surgical procedure (e.g., stereotactic biopsy within  days of first study treatment; placement of a vascular access device within  days of first study treatment).
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day  of FOLFIRI + bevacizumab initiation
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to Day 
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to study enrollment
+Patients are excluded if they have had a biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to randomization
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  calendar days prior to the first dose of bevacizumab
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
+Core biopsy or other minor surgical procedure (excluding placement of a vascular access device, paracentesis, and/or thoracentesis) within  days prior to the first date of bevacizumab therapy
+Patients must not have experienced a core biopsy or other minor surgical procedure within  days prior to registration; NOTE: this excludes placement of a vascular access device up to  days prior to registration
+Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
+Less than  days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
+Care biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day ; (minor surgical procedures include minimally invasive procedures such as fine needle aspiration, core biopsy, etc. requiring little if any supportive care excluding lumbar puncture and bone marrow aspiration/biopsy)
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device within  days prior to starting drug
+(continued from no. ) Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to the first date of bevacizumab therapy
+Minor surgical procedure(s) within  days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ?  day before enrollment is acceptable)
+Any surgical procedure, excluding central venous catheter placement, bone marrow biopsy, lumbar puncture, or other minor procedures (e.g., skin biopsy) within  days of day ; patients who have undergone major surgery =<  days prior to starting study drug or who have not recovered from side effects of such procedure are ineligible for the study
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to Day 
+Patients may not have had a core biopsy, skin cancer resection, or other minor surgical procedure, including placement of a vascular access device, within  days prior to Day  of the protocol.
+Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within  days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days
+Core biopsy or other minor surgical procedure within  days prior to study start
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
+Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to the first dose of bevacizumab or vanucizumab